Skip to main content

Articles

Page 13 of 39

  1. Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have h...

    Authors: Julio García-Suárez, Javier de la Cruz, Ángel Cedillo, Pilar Llamas, Rafael Duarte, Víctor Jiménez-Yuste, José Ángel Hernández-Rivas, Rodrigo Gil-Manso, Mi Kwon, Pedro Sánchez-Godoy, Pilar Martínez-Barranco, Blanca Colás-Lahuerta, Pilar Herrera, Laurentino Benito-Parra, Adrián Alegre, Alberto Velasco…
    Citation: Journal of Hematology & Oncology 2020 13:133
    Content type: Research Published on:

  2. Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of pati...

    Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…
    Citation: Journal of Hematology & Oncology 2020 13:132
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:34

  3. SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B c...

    Authors: Guido Lancman, John Mascarenhas and Michal Bar-Natan
    Citation: Journal of Hematology & Oncology 2020 13:131
    Content type: Letter to the Editor Published on:

  4. Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using ne...

    Authors: Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu and Chen Liu
    Citation: Journal of Hematology & Oncology 2020 13:130
    Content type: Review Published on:

  5. Increasing evidence suggests that high-density lipoprotein (HDL) may play a role in cancer development. We tested the hypothesis that low HDL levels are associated with increased risk of cancer.

    Authors: Kasper Mønsted Pedersen, Yunus Çolak, Stig Egil Bojesen and Børge Grønne Nordestgaard
    Citation: Journal of Hematology & Oncology 2020 13:129
    Content type: Research Published on:

  6. Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However, there has been no appropriate integrative analysis on the hierarchy of dif...

    Authors: Junqing Wu, Yanyu Xiao, Jie Sun, Huiyu Sun, Haide Chen, Yuanyuan Zhu, Huarui Fu, Chengxuan Yu, Weigao E., Shujing Lai, Lifeng Ma, Jiaqi Li, Lijiang Fei, Mengmeng Jiang, Jingjing Wang, Fang Ye…
    Citation: Journal of Hematology & Oncology 2020 13:128
    Content type: Research Published on:

  8. The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has recently gained interest, and different DDR inhibitors have been developed. Among them, the most promising ones target the...

    Authors: Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Hematology & Oncology 2020 13:126
    Content type: Review Published on:

  9. B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including ant...

    Authors: Bo Yu, Tianbo Jiang and Delong Liu
    Citation: Journal of Hematology & Oncology 2020 13:125
    Content type: Review Published on:

  10. Extrachromosomal circular DNA was recently found to be particularly abundant in multiple human cancer cells, although its frequency varies among different tumor types. Elevated levels of extrachromosomal circu...

    Authors: Yuanliang Yan, Guijie Guo, Jinzhou Huang, Ming Gao, Qian Zhu, Shuangshuang Zeng, Zhicheng Gong and Zhijie Xu
    Citation: Journal of Hematology & Oncology 2020 13:124
    Content type: Review Published on:

  11. Conventional therapeutic approaches for tumor angiogenesis, which are primarily focused on the inhibition of active angiogenesis to starve cancerous cells, target the vascular endothelial growth factor signali...

    Authors: Young Sun Choi, Hyeonha Jang, Biki Gupta, Ji-Hak Jeong, Yun Ge, Chul Soon Yong, Jong Oh Kim, Jong-Sup Bae, Im-Sook Song, In-San Kim and You Mie Lee
    Citation: Journal of Hematology & Oncology 2020 13:123
    Content type: Research Published on:

  12. Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scF...

    Authors: Runxia Gu, Fang Liu, Dehui Zou, Yingxi Xu, Yang Lu, Bingcheng Liu, Wei Liu, Xiaojuan Chen, Kaiqi Liu, Ye Guo, Xiaoyuan Gong, Rui Lv, Xia Chen, Chunlin Zhou, Mengjun Zhong, Huijun Wang…
    Citation: Journal of Hematology & Oncology 2020 13:122
    Content type: Research Published on:

  13. Non-coding RNAs (ncRNAs) have been the focus of many studies over the last few decades, and their fundamental roles in human diseases have been well established. Transfer RNAs (tRNAs) are housekeeping ncRNAs t...

    Authors: Mengqian Yu, Bingjian Lu, Jisong Zhang, Jinwang Ding, Pengyuan Liu and Yan Lu
    Citation: Journal of Hematology & Oncology 2020 13:121
    Content type: Review Published on:

  14. Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic state that places them at a dramatically increased lethal risk. Although platelet activation is critical for thrombosis and is respo...

    Authors: Si Zhang, Yangyang Liu, Xiaofang Wang, Li Yang, Haishan Li, Yuyan Wang, Mengduan Liu, Xiaoyan Zhao, Youhua Xie, Yan Yang, Shenghui Zhang, Zhichao Fan, Jianzeng Dong, Zhenghong Yuan, Zhongren Ding, Yi Zhang…
    Citation: Journal of Hematology & Oncology 2020 13:120
    Content type: Research Published on:

  15. Tumor metastasis accounts for the majority of cancer-related deaths; it is therefore important to develop preclinical models that faithfully recapitulate disease progression. Here, we generated paired organoid...

    Authors: He Li, Weixing Dai, Xi Xia, Renjie Wang, Jing Zhao, Lingyu Han, Shaobo Mo, Wenqiang Xiang, Lin Du, Guangya Zhu, Jingjing Xie, Jun Yu, Nan Liu, Mingzhu Huang, Jidong Zhu and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2020 13:119
    Content type: Letter to the Editor Published on:

  16. Synthetic lethality is a lethal phenomenon in which the occurrence of a single genetic event is tolerable for cell survival, whereas the co-occurrence of multiple genetic events results in cell death. The main...

    Authors: Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen and Xiujun Cai
    Citation: Journal of Hematology & Oncology 2020 13:118
    Content type: Review Published on:

  17. N6-methyladenosine (m6A) is the most abundant mRNA modification and is catalyzed by the methyltransferase complex, in which methyltransferase-like 3 (METTL3) is the sole catalytic subunit. Accumulating evidence i...

    Authors: Chengwu Zeng, Wanxu Huang, Yangqiu Li and Hengyou Weng
    Citation: Journal of Hematology & Oncology 2020 13:117
    Content type: Review Published on:

  18. High mobility group box 1 (HMGB1) is a non-histone chromatin-associated protein widely distributed in eukaryotic cells and is involved in DNA damage repair and genomic stability maintenance. In response to sti...

    Authors: Shumin Wang and Yi Zhang
    Citation: Journal of Hematology & Oncology 2020 13:116
    Content type: Editorial Published on:

  19. Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethaso...

    Authors: Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder…
    Citation: Journal of Hematology & Oncology 2020 13:115
    Content type: Research Published on:

  20. Eph receptors and the corresponding Eph receptor-interacting (ephrin) ligands jointly constitute a critical cell signaling network that has multiple functions. The tyrosine kinase EphA2, which belongs to the f...

    Authors: Ta Xiao, Yuhang Xiao, Wenxiang Wang, Yan Yan Tang, Zhiqiang Xiao and Min Su
    Citation: Journal of Hematology & Oncology 2020 13:114
    Content type: Review Published on:

  22. ETV4 is one of the ETS proteins overexpressed in prostate cancer (PC) as a result of recurrent chromosomal translocations. In human prostate cell lines, ETV4 promotes migration, invasion, and proliferation; ho...

    Authors: Irene Cosi, Annamaria Pellecchia, Emanuele De Lorenzo, Eugenio Torre, Michela Sica, Gabriella Nesi, Rosario Notaro and Maria De Angioletti
    Citation: Journal of Hematology & Oncology 2020 13:112
    Content type: Research Published on:

  23. Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed treatment in solid tumor oncology. ...

    Authors: Basit Salik, Mark J. Smyth and Kyohei Nakamura
    Citation: Journal of Hematology & Oncology 2020 13:111
    Content type: Review Published on:

  24. In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has achieved considerable success in the clinic. However, ICIs are significantly limited by the fact that only one third of pa...

    Authors: Rong Tang, Jin Xu, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Xianjun Yu and Si Shi
    Citation: Journal of Hematology & Oncology 2020 13:110
    Content type: Review Published on:

  25. Noncoding RNAs (ncRNAs) are a large segment of the transcriptome that do not have apparent protein-coding roles, but they have been verified to play important roles in diverse biological processes, including d...

    Authors: Yu-Meng Sun and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2020 13:109
    Content type: Review Published on:

  26. Multiple Myeloma (MM) is a hematological malignancy with genomic heterogeneity and poor survival outcome. Apart from the central role of genetic lesions, epigenetic anomalies have been identified as drivers in...

    Authors: Samrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, Michael Bauer, Yan Wang, Shayu Deshpande, Judith Den, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies, Frits van Rhee, Gareth J. Morgan and Brian A. Walker
    Citation: Journal of Hematology & Oncology 2020 13:108
    Content type: Research Published on:

  27. As crucial antigen presenting cells, dendritic cells (DCs) play a vital role in tumor immunotherapy. Taking into account the many recent advances in DC biology, we discuss how DCs (1) recognize pathogenic anti...

    Authors: Yingying Wang, Ying Xiang, Victoria W. Xin, Xian-Wang Wang, Xiao-Chun Peng, Xiao-Qin Liu, Dong Wang, Na Li, Jun-Ting Cheng, Yan-Ning Lyv, Shu-Zhong Cui, Zhaowu Ma, Qing Zhang and Hong-Wu Xin
    Citation: Journal of Hematology & Oncology 2020 13:107
    Content type: Review Published on:

  28. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su
    Citation: Journal of Hematology & Oncology 2020 13:106
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:135

  29. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of ...

    Authors: Yu Chen, Min Gao, Zhaoqin Huang, Jinming Yu and Xiangjiao Meng
    Citation: Journal of Hematology & Oncology 2020 13:105
    Content type: Review Published on:

  30. Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of Lys-27 in histone 3 (H3K27me3). ...

    Authors: Ran Duan, Wenfang Du and Weijian Guo
    Citation: Journal of Hematology & Oncology 2020 13:104
    Content type: Review Published on:

  31. Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to con...

    Authors: Yonghan He, Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu, Yaxia Yuan, Robert Hromas, Mingjiang Xu, Guangrong Zheng and Daohong Zhou
    Citation: Journal of Hematology & Oncology 2020 13:103
    Content type: Review Published on:

  32. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Sha-Sha Cheng, Guan-Jun Yang, Wanhe Wang, Chung-Hang Leung and Dik-Lung Ma
    Citation: Journal of Hematology & Oncology 2020 13:102
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:26

  33. MicroRNAs (miRNAs) play important roles in cell proliferation, differentiation, and survival and may be useful for acute myeloid leukemia (AML) diagnosis and prognosis. In this study, we defined a novel miRNA,...

    Authors: Yan Jia, Wei Liu, Hui-En Zhan, Xiao-Ping Yi, Hui Liang, Qi-Li Zheng, Xin-Ya Jiang, Hai-Yan Zhou, Liang Zhao, Xie-Lan Zhao and Hui Zeng
    Citation: Journal of Hematology & Oncology 2020 13:101
    Content type: Letter to the Editor Published on:

  34. Both inflammasomes and autophagy have important roles in the intracellular homeostasis, inflammation, and pathology; the dysregulation of these processes is often associated with the pathogenesis of numerous c...

    Authors: Chaeuk Chung, Wonhyoung Seo, Prashanta Silwal and Eun-Kyeong Jo
    Citation: Journal of Hematology & Oncology 2020 13:100
    Content type: Review Published on:

  35. The cyclin-dependent kinase 7 (CDK7) subunit of TFIIH regulates RNA polymerase-II-based transcription and promotes tumor progression. However, the mechanisms involved in CDK7-mediated immune evasion are unclea...

    Authors: Jian Wang, Ruiguang Zhang, Zhenyu Lin, Sheng Zhang, Yaobing Chen, Jing Tang, Jiaxin Hong, Xiaoshu Zhou, Yan Zong, Yingzhuo Xu, Rui Meng, Shuangbing Xu, Li Liu, Tao Zhang, Kunyu Yang, Xiaorong Dong…
    Citation: Journal of Hematology & Oncology 2020 13:99
    Content type: Research Published on:

  36. Investigations of disease incidence, mortality, and disability-adjusted life years (DALYs) are valuable for facilitating preventive measures and health resource planning. We examined the tracheal, bronchus, an...

    Authors: Yujiao Deng, Peng Zhao, Linghui Zhou, Dong Xiang, Jingjing Hu, Yu Liu, Jian Ruan, Xianghua Ye, Yi Zheng, Jia Yao, Zhen Zhai, Shuqian Wang, Si Yang, Ying Wu, Na Li, Peng Xu…
    Citation: Journal of Hematology & Oncology 2020 13:98
    Content type: Research Published on:

  37. Cancer is a complex disease in which both genetic defects and microenvironmental components contribute to the development, progression, and metastasization of disease, representing major hurdles in the identif...

    Authors: Michele Zanoni, Michela Cortesi, Alice Zamagni, Chiara Arienti, Sara Pignatta and Anna Tesei
    Citation: Journal of Hematology & Oncology 2020 13:97
    Content type: Review Published on:

  38. CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending...

    Authors: Entsar Eladl, Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Rumina Musani, Wenming Chen, Aijun Liu and Hong Chang
    Citation: Journal of Hematology & Oncology 2020 13:96
    Content type: Review Published on:

  39. Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins. Subsets of TC...

    Authors: Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T. Ortiz, Xin Zhang, Dongwen Lv, Janet S. Wiegand, Wen Li, Adam C. Palmer, Guangrong Zheng, David M. Weinstock and Daohong Zhou
    Citation: Journal of Hematology & Oncology 2020 13:95
    Content type: Research Published on:

  40. The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during the pandemic in New York City. The pandemic dir...

    Authors: Bo Wang, Oliver Van Oekelen, Tarek H. Mouhieddine, Diane Marie Del Valle, Joshua Richter, Hearn Jay Cho, Shambavi Richard, Ajai Chari, Sacha Gnjatic, Miriam Merad, Sundar Jagannath, Samir Parekh and Deepu Madduri
    Citation: Journal of Hematology & Oncology 2020 13:94
    Content type: Research Published on:

  42. The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-la...

    Authors: Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan and Michael Heuser
    Citation: Journal of Hematology & Oncology 2020 13:92
    Content type: Research Published on:

  44. RNA-binding protein (RBP) has a highly dynamic spatiotemporal regulation process and important biological functions. They are critical to maintain the transcriptome through post-transcriptionally controlling t...

    Authors: Hai Qin, Haiwei Ni, Yichen Liu, Yaqin Yuan, Tao Xi, Xiaoman Li and Lufeng Zheng
    Citation: Journal of Hematology & Oncology 2020 13:90
    Content type: Review Published on:

  45. The oncolytic viruses have shown promising results for the treatment of multiple myeloma. However, the use of human viruses is limited by the patients’ antiviral immune response. In this study, we investigated...

    Authors: Valentina Marchica, Valentina Franceschi, Rosanna Vescovini, Paola Storti, Emanuela Vicario, Denise Toscani, Alessia Zorzoli, Irma Airoldi, Benedetta Dalla Palma, Nicoletta Campanini, Eugenia Martella, Cristina Mancini, Federica Costa, Gaetano Donofrio and Nicola Giuliani
    Citation: Journal of Hematology & Oncology 2020 13:89
    Content type: Research Published on:

  46. Due to acromegaly’s insidious onset and slow progression, its diagnosis is usually delayed, thus causing severe complications and treatment difficulty. A convenient screening method is imperative. Based on our...

    Authors: Yanguo Kong, Xiangyi Kong, Cheng He, Changsong Liu, Liting Wang, Lijuan Su, Jun Gao, Qi Guo and Ran Cheng
    Citation: Journal of Hematology & Oncology 2020 13:88
    Content type: Letter to the Editor Published on:

  47. Graft-versus-host disease (GVHD) remains a major contributor to mortality and morbidity after allogeneic stem-cell transplantation (allo-HSCT). The updated recommendations suggest that rabbit antithymocyte glo...

    Authors: Eolia Brissot, Myriam Labopin, Ian Moiseev, J. J. Cornelissen, Ellen Meijer, Gwendolyn Van Gorkom, Montserrat Rovira, Fabio Ciceri, Laimonas Griskevicius, Didier Blaise, Edouard Forcade, Martin Mistrik, Stephan Mielke, Claude Eric Bulabois, Riitta Niittyvuopio, Eric Deconinck…
    Citation: Journal of Hematology & Oncology 2020 13:87
    Content type: Research Published on:

  48. Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 C...

    Authors: Ruihao Huang, Xiaoping Li, Yundi He, Wen Zhu, Lei Gao, Yao Liu, Li Gao, Qin Wen, Jiang F. Zhong, Cheng Zhang and Xi Zhang
    Citation: Journal of Hematology & Oncology 2020 13:86
    Content type: Review Published on:

  49. Alpha-fetoprotein (AFP) is a widely used biomarker for hepatocellular carcinoma (HCC) early detection. However, low sensitivity and false negativity of AFP raise the requirement of more effective early diagnos...

    Authors: Shu Zhang, Yuming Liu, Jing Chen, Hong Shu, Siyun Shen, Yin Li, Xinyuan Lu, Xinyi Cao, Liangqing Dong, Jieyi Shi, Ya Cao, Xiaoying Wang, Jian Zhou, Yinkun Liu, Lei Chen, Jia Fan…
    Citation: Journal of Hematology & Oncology 2020 13:85
    Content type: Research Published on:

  50. VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer i...

    Authors: Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, Xueli Bai and Tingbo Liang
    Citation: Journal of Hematology & Oncology 2020 13:83
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us